AAAAAA
Results: 1-25/30
Authors:
Mathijssen, RHJ
van Alphen, RJ
Verweij, J
Loos, WJ
Nooter, K
Stoter, G
Sparreboom, A
Citation: Rhj. Mathijssen et al., Clinical pharmacokinetics and metabolism of irinotecan (CPT-11), CLIN CANC R, 7(8), 2001, pp. 2182-2194
Authors:
Polee, MB
Kok, TC
Siersema, PD
Tilanus, NW
Splinter, TAW
Stoter, G
Van der Gaast, A
Citation: Mb. Polee et al., Phase II study of the combination cisplatin, etoposide, 5-fluorouracil andfolinic acid in patients with advanced squamous cell carcinoma of the esophagus, ANTI-CANC D, 12(6), 2001, pp. 513-517
Authors:
de Jongh, FE
Verweij, J
Loos, WJ
de Wit, R
de Jonge, MJA
Planting, AST
Nooter, K
Stoter, G
Sparreboom, A
Citation: Fe. De Jongh et al., Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure, J CL ONCOL, 19(17), 2001, pp. 3733-3739
Authors:
van Zuylen, L
Karlsson, MO
Verweij, J
Brouwer, E
de Bruijn, P
Nooter, K
Stoter, G
Sparreboom, A
Citation: L. Van Zuylen et al., Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles, CANC CHEMOT, 47(4), 2001, pp. 309-318
Authors:
Tjan-Heijnen, VCG
Groen, HJM
Schramel, FMNH
Stoter, G
Citation: Vcg. Tjan-heijnen et al., Consensus conference on palliative treatment of stage IV non-small cell lung cancer - Consensus Meeting of the Netherlands Society for Medical Oncology and the Taskforce on Lung Cancer of the Dutch Society of Physicians for Lung Diseases and Tuberculosis, NETH J MED, 58(2), 2001, pp. 52-61
Authors:
Schenk, PW
Boersma, AWM
Brandsma, JA
den Dulk, H
Burger, H
Stoter, G
Brouwer, J
Nooter, K
Citation: Pw. Schenk et al., SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line, CANCER RES, 61(19), 2001, pp. 6982-6986
Authors:
Portielje, JEA
Kruit, WHJ
Eerenberg, AJM
Schuler, M
Sparreboom, A
Lamers, CHJ
Bolhuis, RLH
Stoter, G
Huber, C
Hack, CE
Citation: Jea. Portielje et al., Interleukin 12 induces activation of fibrinolysis and coagulation in humans, BR J HAEM, 112(2), 2001, pp. 499-505
Authors:
Schuyer, M
van der Burg, MEL
Henzen-Logmans, SC
Fieret, JH
Klijn, JGM
Look, MP
Foekens, JA
Stoter, G
Berns, EMJJ
Citation: M. Schuyer et al., Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2, BR J CANC, 85(9), 2001, pp. 1359-1367
Authors:
de Wit, R
de Boer, AC
von der Linden, GHM
Stoter, G
Sparreboom, A
Verweij, J
Citation: R. De Wit et al., Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy, BR J CANC, 85(8), 2001, pp. 1099-1101
Authors:
Loos, WJ
Kehrer, D
Brouwer, E
Verweij, J
de Bruijn, P
Hamilton, M
Gill, S
Nooter, K
Stoter, G
Sparreboom, A
Citation: Wj. Loos et al., Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography, J CHROMAT B, 738(1), 2000, pp. 155-163
Authors:
van Zuylen, L
Verweij, J
Nooter, K
Brouwer, E
Stoter, G
Sparreboom, A
Citation: L. Van Zuylen et al., Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans, CLIN CANC R, 6(7), 2000, pp. 2598-2603
Authors:
Kruit, WHJ
Eggermont, AMM
Stoter, G
Citation: Whj. Kruit et al., Interferon-alpha induced Raynaud's syndrome, ANN ONCOL, 11(11), 2000, pp. 1501-1502
Authors:
Eskens, FALM
Stoter, G
Verweij, J
Citation: Falm. Eskens et al., Farnesyl transferase inhibitors: current developments and future perspectives, CANC TR REV, 26(5), 2000, pp. 319-332
Authors:
Stam, TC
Swaak, AJG
Kruit, WHJ
Stoter, G
Eggermont, AMM
Citation: Tc. Stam et al., Intrapleural administration of tumour necrosis factor-alpha (TNF alpha) inpatients with mesothelioma: cytokine patterns and acute-phase protein response, EUR J CL IN, 30(4), 2000, pp. 336-343
Authors:
Burger, H
Capello, A
Schenk, PW
Stoter, G
Brouwer, J
Nooter, K
Citation: H. Burger et al., A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin, BIOC BIOP R, 269(3), 2000, pp. 767-774
Authors:
Loos, WJ
de Bruijn, P
van Zuylen, L
Verweij, J
Nooter, K
Stoter, G
Sparreboom, A
Citation: Wj. Loos et al., Determination of 5-fluorouracil in microvolumes of human plasma by solventextraction and high-performance liquid chromatography, J CHROMAT B, 735(2), 1999, pp. 293-297
Authors:
Sparreboom, A
Loos, WJ
Nooter, K
Stoter, G
Verweij, J
Citation: A. Sparreboom et al., Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel, J CHROMAT B, 735(1), 1999, pp. 111-119
Authors:
de Jonge, MJA
Verweij, J
Planting, AST
van der Burg, MEL
Stoter, G
de Boer-Dennert, MM
de Bruijn, P
Brouwer, E
Vernillet, L
Sparreboom, A
Citation: Mja. De Jonge et al., Drug-administration sequence does not change pharmacodynamics and kineticsof irinotecan and cisplatin, CLIN CANC R, 5(8), 1999, pp. 2012-2017
Authors:
Portielje, JEA
Kruit, WHJ
Schuler, M
Beck, J
Lamers, CHJ
Stoter, G
Huber, C
de Boer-Dennert, M
Rakhit, A
Bolhuis, RLH
Waiter, E
Citation: Jea. Portielje et al., Phase I study of subcutaneously administered recombinant human interleukin12 in patients with advanced renal cell cancer, CLIN CANC R, 5(12), 1999, pp. 3983-3989
Authors:
Planting, AST
Schellens, JHM
van der Burg, MEL
de Boer-Dennert, M
Winograd, B
Stoter, G
Verweij, J
Citation: Ast. Planting et al., Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors, ANTI-CANC D, 10(9), 1999, pp. 821-827
Authors:
van Zuylen, L
Schellens, JHM
Goey, SH
Pronk, LC
de Boer-Dennert, MM
Loos, WJ
Ma, JG
Stoter, G
Verweij, J
Citation: L. Van Zuylen et al., Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combinationwith cisplatin and etoposide in patients with non-small cell lung cancer, ANTI-CANC D, 10(4), 1999, pp. 361-368
Authors:
Mathijssen, RHJ
van Alphen, RJ
de Jonge, MJA
Verweij, J
de Bruijn, P
Loos, WJ
Nooter, K
Vernillet, L
Stoter, G
Sparreboom, A
Citation: Rhj. Mathijssen et al., Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin, ANTI-CANC D, 10(1), 1999, pp. 9-16
Authors:
Pronk, LC
van Putten, WLJ
van Beurden, V
de Boer-Dennert, M
Stoter, G
Verweij, J
Citation: Lc. Pronk et al., The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study, CANC CHEMOT, 43(2), 1999, pp. 173-177
Authors:
Kruit, WHJ
Schmitz, PIM
Stoter, G
Citation: Whj. Kruit et al., The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells, CANCER IMMU, 48(6), 1999, pp. 331-335
Authors:
Sparreboom, A
De Jonge, MJA
Punt, CJA
Loos, WJ
Nooter, K
Stoter, G
Porro, MG
Verweij, J
Citation: A. Sparreboom et al., Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis, DRUG META D, 27(7), 1999, pp. 816-820